Xinyuan Wu,Michael A Marchetti,Ashfaq A Marghoob
Xinyuan Wu
Use of dermoscopy has been proven to increase diagnostic accuracy for melanoma. It is frequently used by dermatologists and other healthcare providers during skin cancer screening and in the evaluation of concerning skin lesions. Studies ha...
Candy Wyatt,Rachel E Neale,Robyn M Lucas
Candy Wyatt
Exposure of the skin to solar ultraviolet (UV) radiation has both risks and benefits for human health. Absorption of UV-B radiation by DNA results in mutations that underlie the development of skin cancers, as is apparent from genetic studi...
Ester Simeone,Antonio M Grimaldi,Paolo A Ascierto
Ester Simeone
Programmed cell death receptor-1 (PD-1) and programmed cell death-1 ligand-1 (PD-L1) represent promising novel targets in immunotherapy. PD-1 is an inhibitory receptor involved in T-cell regulation that is expressed by activated T cells. Ni...
Shikha Jain,Joseph I Clark
Shikha Jain
Melanoma is the sixth most common cancer in the US. Metastatic melanoma has increased in incidence over the past 30 years. In the US approximately 8600 people died from melanoma in 2009. It is an aggressive tumor; the prognosis of stage IV ...
Electrochemotherapy: a good idea in recurrent basal cell carcinoma treatment [0.03%]
电化学治疗复发基底细胞癌的好方法
Roberta Ruggeri,Andrea Maurichi,Maria Carla Tinti et al.
Roberta Ruggeri et al.
Basal cell carcinoma (BCC) is the most common skin cancer in Caucasian population. Surgical excision is the gold standard treatment for BCC. Secondary surgical approach in patients presenting surgical scars after multiple surgical excisions...
Case Reports
Melanoma management. 2015 Feb;2(1):27-31. DOI:10.2217/mmt.14.28 2015
Is histopathological overdiagnosis of melanoma a good insurance for the future? [0.03%]
过度诊断黑色素瘤是对未来的良好预防措施吗？
Gerardo Ferrara,Iris Zalaudek
Gerardo Ferrara
Synergistic effects of MAPK and immune checkpoint inhibitors in melanoma: what is the best combination strategy? [0.03%]
MAPK和免疫检查点抑制剂在黑色素瘤中的协同作用：最佳联合策略是什么？
James S Wilmott,Peter Hersey,Georgina V Long et al.
James S Wilmott et al.
Combination approaches and anti-PD1 therapies: the focus of new research at ESMO and SMR [0.03%]
ESMO和SABR大会上新的研究重点：联合疗法和抗PD-1疗法
Paolo A Ascierto
Paolo A Ascierto
Research into the treatment of melanoma is continuing to progress, and both the European Society of Medical Oncology (26-30 September, Madrid, Spain) and the Society of Melanoma Research (13-16 November, Zurich, Switzerland) 2014 annual mee...
Immunohistochemistry for an improved clinical workflow in the era of personalized melanoma therapy? [0.03%]
免疫组化在个性化黑色素瘤治疗时代的临床工作流程中的应用？
Daniela Massi,Mario Mandalà
Daniela Massi
Barriers to risk-understanding and risk-reduction behaviors among individuals with a family history of melanoma [0.03%]
具有黑色素瘤家族史的个体进行风险认识和降低风险行为的障碍
Laura Fitzpatrick,Jennifer L Hay
Laura Fitzpatrick
Family members of melanoma patients are often called upon to provide support, ranging from monetary to medical assistance. Consanguineal relatives of melanoma patients are also at greater risk of developing the disease themselves. However, ...